



APOTEX

Canadian-Based
Global Health Company

2025 SUSTAINABILITY REPORT

A Force for Health

Table of contents

3	CEO letter
---	------------

4	Introduction	5	Apotex by the numbers
		6	About this report

7	Sustainability at Apotex	7	Our ethos
		8	Stakeholder engagement

9	Patient wellbeing	10	Product quality & safety
		11	Access & patient support
		11	Responsible labeling

12	Governance	12	Corporate governance
		12	Business integrity
		13	Cybersecurity & data privacy

14	Environmental impact	14	GHG emissions & climate change
		17	Green chemistry
		17	Waste
		17	Water
		17	Air emissions

18	Social impact	18	Health & safety
		19	Talent attraction, retention, & development
		19	Supplier engagement
		20	Corporate citizenship

21	Appendix
----	----------



CEO letter

Apotex’s 2025 Sustainability Report reflects our commitment to being A Force for Health—advancing access to medicines with urgency and purpose, aiming to deliver uncompromising quality, and unlocking new possibilities for patients, consumers, and communities through meaningful partnerships. This report provides an update on our environmental, social, and governance activities.

As the largest Canadian-based pharmaceutical company and a trusted partner across the Americas, we recognize the important role we play in supporting the health journeys of millions of people.

This past year, we continued to translate that commitment into action:

- We supported more sustainable healthcare systems globally by expanding access to high-quality generic medicines. In Canada alone, Apotex products have delivered more than \$11 billion in savings over the past five years, and more than \$50 billion over the past five decades.
- Through more than 20 years of partnership with Health Partners International Canada, we have donated over \$46 million in products, reaching communities in nearly 80 countries and helping address urgent healthcare needs where they matter most.
- We made progress on our environmental commitments, with 78% of our global electricity consumption sourced from renewable or low carbon energy.

While we are proud of this progress, we are just as focused on what comes next. In the year ahead, we will continue to advance resource efficiency and deliver accessible, high-quality generics, innovative branded pharmaceuticals, biosimilars, and consumer health products that patients need.

Equally important is how we invest in our people. We remain committed to fostering an innovative, inclusive, and performance-driven workplace where talent can thrive.

Sustainability at Apotex is not a standalone effort, it is embedded in how we operate, innovate, and grow. As expectations evolve, we will continue to listen to our stakeholders while measuring our impact more rigorously and holding ourselves accountable for continued progress.


Jeff Watson
President and CEO

Introduction

Apotex is the largest Canadian-based global health company and a trusted health partner for pharmaceutical licensing, product acquisitions, and commercialization throughout the Americas.

Our diversified global portfolio includes more than 800 generic and branded prescriptions, over-the-counter products, biosimilar pharmaceutical products across all major therapeutic areas, and a complementary portfolio of consumer health products. Delivering reliable products for more than 50 years, we have earned the trust of healthcare professionals and patients worldwide.

An extensive global presence in research and development, manufacturing, and commercialization upholds our long-standing commitments to innovation and sustainability, driving efficiency throughout our operations. We have the capacity to produce 25 billion finished doses across our manufacturing sites in Canada, Mexico, and India, with sales in more than 70 countries. Our efforts centre on certain therapeutic areas, including dermatology, neuroscience, oncology, ophthalmology, osteoporosis, pain management, and women's health.

Founded in Toronto, we are proud of our Canadian roots, with our headquarters still located in the city where we began, while our workforce has grown to more than **6,000 employees worldwide.**

We have continued to execute on our Journey of Health strategy to deliver high-quality, affordable medicines that help people live healthier lives at all stages. Our focus is on expanding access and bringing trusted treatments to patients and consumers when they need them most. We diversified our business with the 2024 integration of Searchlight Pharma, the 2025 acquisition of CanPrev, a leading Canadian natural health company, and the integration of two branded products, Provigil® and Nuvigil®, into our U.S. portfolio.



Apotex by the numbers

- ✓ **Canadian Health Champion: #1 in Pharmaceuticals¹**
- ✓ **Global reach: Top 10 player by Gx sales in U.S.² and Mexico³**

1 in 5

generic pharmaceutical prescriptions
in Canada manufactured by Apotex

\$11 billion+

delivered in savings
for the Canadian
healthcare
system over the
past five years

25 billion

finished doses in annual production capacity

800+

products in a robust
portfolio

70+

new products
launched annually

Focused leader in U.S. generics:

#1 nasal
manufacturer

#3 oncology
manufacturer

6,000+

people around
the world

About this report

This report outlines the environmental, social, and governance (ESG) matters that impact our organization, as well as actions we are taking to shape a sustainable future for all our stakeholders. It encompasses all affiliates and divisions of Apotex Inc. All data represents calendar year January 1, 2025 through December 31, 2025, unless otherwise stated.

All financial figures are Canadian dollars, unless otherwise stated.
This report was developed in accordance with Sustainability Accounting Standards Board (SASB) standards for the Biotechnology & Pharmaceuticals sector.



Sustainability at Apotex



Our ethos

Our values of integrity, courage, teamwork, and innovation are at the heart of everything we do. They guide how we operate and how we seek to deliver for patients—shaping the science behind our research, our approach to manufacturing, and the quality of every product we bring to people around the world.




At Apotex, our **Winning Behaviours** define how we turn intent into action:



INDIVIDUAL ACCOUNTABILITY

“I do what I say I will do.”



RIGOUR AND DISCIPLINE

“I make plans and deliver results.”



CONTINUOUS IMPROVEMENT

“I always strive to do better.”

Rooted in this mindset, we are committed to supporting people at every stage of their health journeys. Our teams are driven not only to deliver high-quality, accessible medicines, but to do so in ways that create lasting value for society and reduce our impact on the environment.

We also recognize that improving health goes beyond the products we make. It means contributing to stronger, more resilient communities. Patients remain at the centre of our thinking, inspiring us to collaborate more closely with the broader healthcare ecosystem, design more responsive support programs, and address unmet needs with purpose and urgency.

Stakeholder engagement

We believe meaningful progress starts with listening. Maintaining open, transparent dialogue with stakeholders across our value chain is essential to how we operate and how we continue to improve.

In 2025, we continued our participation in leading disclosure frameworks, including CDP, formerly known as the Carbon Disclosure Project, where we report on climate-related risks, opportunities, and performance. We also maintained our disclosure through EcoVadis, providing customers and partners with clear insight into how we manage environmental and social risks across our operations and value chain.



Patient wellbeing

Patient wellbeing drives our commitment to innovation, sustainability, and responsible business practices.

For more than 50 years, we have focused on improving healthcare outcomes through affordable medications and supporting patient-focused programs that address evolving needs.

We contribute to the sustainability of the healthcare system through a broad portfolio of 680+ products in Canada and 800+ products globally.



HIGHLIGHT STORY

Sunnybrook Foundation Cancer Care at Home

In October 2025, we helped bring oncology care directly into patients' homes through a \$1.5 million donation to Sunnybrook Foundation. The contribution supported the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.

Cancer Care at Home combines remote monitoring, urgent oncology support and hospital-to-home services to create a seamless care pathway. The program aims to reduce emergency visits, ease transitions after hospital stays, and provide guidance between appointments.



Product quality & safety

We prioritize product quality and safety. Our comprehensive quality management systems seek to ensure compliance with global regulations and maintain the trust of patients and business partners. This system incorporates audits, regulatory inspections, metrics and measurements for continuous improvement followed by continuous monitoring to meet stringent standards, including those set by Health Canada and the U.S. Food and Drug Administration (FDA).

Senior leaders in our Global Quality and Compliance functions oversee regulatory alignment, risk management, CGMP compliance and process improvement. They foster accountability and strive to stay ahead of evolving global requirements as we seek to ensure Apotex maintains its quality objectives. Through rigorous oversight at every stage, from raw material verification to monitoring manufacturing conditions and finished product testing, we seek to uphold high standards of product quality, safety, efficacy, and product stability.

In 2025, we underwent 18 inspections by applicable regulatory agencies, with all but one inspection resulting in a compliant rating. Between April and May 2025, our Richmond Hill finished dosage manufacturing facility was inspected by both the FDA and Health Canada. While observations were identified during these inspections, Health Canada accepted our remediation plans and rated the facility Compliant. The FDA classified the facility as Official Action Indicated (OAI) and issued a Warning Letter related to cGMP observations. We responded with a comprehensive remediation plan and continue to work closely with the FDA to address all findings. Through the implementation of our corrective and preventive actions, together with continued engagement with regulators, our actions are intended to further strengthen our quality systems, governance, quality culture, and long-term compliance capabilities, reinforcing our commitment to product quality, patient safety, and regulatory compliance.

Employees at Apotex receive comprehensive training to understand their role in product quality and safety, helping to embed quality and compliance throughout our organization and support a culture of continuous improvement.

Access & patient support

As a North American leader in pharmaceuticals and consumer healthcare, Apotex plays a vital role in improving access to affordable healthcare. Through our global generics business, we offer cost-effective alternatives to branded medications and provide patients with the same quality, safety, and efficacy at significantly lower costs. We also in-license products from other jurisdictions through our branded division Searchlight Pharma, making these products available in Canada.

For individuals facing financial challenges, generics can be a lifeline to accessing essential medications. Through efficient production processes and economies of scale, we manufacture generics that meet rigorous regulatory standards while delivering substantial cost savings to both patients and healthcare systems.

To address remaining financial barriers, we offer programs, including [ApoAssist](#)⁴ and [Apotex 360](#)⁵, that provide eligible patients with reimbursement support, financial aid, and coverage renewal assistance.

Responsible labeling

Responsible communication practices support our mission to inform and empower patients and providers.

Consistent with our regulatory requirements, we seek to ensure all product labels, packaging, and marketing materials clearly communicate usage, benefits, risks, and potential side effects.



4 ApoAssist is a comprehensive support platform from Apotex that helps healthcare professionals manage prescriptions, patient adherence, and medication information efficiently.

5 Apotex 360 is an intuitive, modern digital platform serving as your all-in-one source for Apotex value-added programs, services, resources, and information.

Governance

Corporate governance

Our governance structure is designed to ensure accountability for Apotex's performance and its future impacts.

Our acquisition by SK Capital in 2023 further enhanced our governing structure, leveraging its industry expertise to strengthen our market leadership and expand global access to affordable, innovative medicines. Our Executive Leadership Team (ELT) reinforces our focus on strong corporate governance and effective decision-making.

Our governance framework is led by the Board of Directors (the Board), which includes representatives from Apotex, SK Capital, and independent directors, working collaboratively to guide the company's strategic direction.

We enhanced our Enterprise Risk Management program and conducted a comprehensive risk assessment, the results of which were reported to the Board. The assessment covered 13 priority areas and helped the Compliance team develop corresponding action plans to manage each identified risk.



Business integrity

Conducting business with integrity is central to our ethos.

We expect employees, suppliers, and business partners to maintain transparent, ethical conduct to protect relationships and uphold our reputation. All Apotex operations are conducted in a way to seek to comply with applicable laws, company policies, and the Code of Conduct and Business Ethics, which outlines expectations on areas such as conflicts of interest, data privacy, anti-corruption, and anti-bribery.

Highlights from our updated 2025 Code of Conduct and Business Ethics include:

- ☒ Online disclosure forms available for employees to report conflicts of interest
- ☒ Education around our Insider Trading Policy
- ☒ A policy on Artificial Intelligence use

All Apotex employees are trained annually on the Code of Conduct.



The Chief Compliance Officer chairs the Risk Oversight and Compliance Committee (ROCC). The ROCC provides oversight and guidance for the Global Business Ethics and Compliance program and serves as an escalation forum for material compliance matters. Regional Business Ethics and Compliance Committees conduct ethics and compliance risk assessments, prioritize high-risk areas, and develop mitigation plans aligned with business objectives. The Chief Compliance Officer also reports quarterly to the Audit Committee of the Board of Directors.

Consisting of nearly 40 global leaders, our Ethics Liaison Network (ELN) works to advocate for a positive ethical culture, distribute compliance program communications, and support training while working with management to identify and address risks.

As part of our Speak Up program, Apotex is committed to creating a safe environment where employees can report suspected compliance issues without fear of retaliation. The [Global Speaking Up Policy](#) outlines the procedures for reporting concerns, how the company will respond, and its strict prohibition against retaliation for good-faith reporting. Our dedicated ethics helpline and centralized reporting system, [APOspeaks](#), supports anonymous reporting 24 hours a day, every day. In 2025, we enhanced our APOspeaks portal with increased anonymity and reporting options.

Cybersecurity & data privacy

Cybersecurity and data privacy are essential for protecting intellectual property and patient, employee, and vendor information.

We conduct continuous threat monitoring, supplemented by penetration tests, to identify potential vulnerabilities and have implemented an internal cybersecurity program aligned with the National Institute of Standards and Technology (NIST) Cybersecurity Framework and healthcare industry best practices.

Our third-party managed incident response plan is designed to help personnel quickly contain, mitigate, and remediate security incidents with minimal disruption to operations.

Beyond our operations, we seek to safeguard against threats that may arise across our value chain, including among our suppliers. Our Global Supplier Code of Conduct establishes minimum standards with regards to data privacy and protection for patient, employee, and customer data, and Apotex intellectual property. Suppliers are expected to maintain appropriate safeguards to protect this data from unauthorized access and improper use, disclosure, modification, theft, or fraud.

Environmental impact

Our Environmental, Health, and Safety (EHS) program supports the commitments made in our global EHS policy. With respect to the environment, the program seeks to ensure regulatory compliance and efficient management of energy, waste and water resources.



GHG emissions & climate change

As part of our commitment to health and resilience, we seek to enhance efficiency and reduce our environmental footprint. In 2025, 78% of our global electricity consumption came from renewable or low-carbon energy sources such as solar and wind. We calculate our Scope 1 and 2 emissions for Apotex’s global footprint in line with the Greenhouse Gas (GHG) Protocol to maintain a clear view of our climate impact and track trends over time.

Total Scope 1 and 2 emissions (tCO₂e)⁶



⁶ Calculation methodology is based on guidance from the GHG Protocol and is consistent throughout all years included in the assessment, as further described below:

- Scope 1 is based on published emission factors for stationary combustion sources (propane, diesel, natural gas), mobile combustion, and refrigerants; and
- Scope 2 is based on published grid intensities for each specific operational year.

⁷ The increase in GHG emissions in 2025 is primarily driven by three factors:

1. The inclusion of the Indianapolis Distribution Centre in the organizational boundary beginning in 2025.
2. Higher reported emissions from the Mexico site were driven by a significant rise in diesel use at the Protein site during an extended power outage that required prolonged generator operation.
3. The Signa site transitioned to a new natural gas supplier, resulting in more accurate consumption data and an updated correction factor, which contributed to higher reported emissions.

☆ 2025 HIGHLIGHTS

Apotex is driving energy efficiency initiatives across our global sites



US Indianapolis waste-to-energy through ReWorld initiative

Our Indianapolis distribution and warehouse site continued advancing circularity and waste-to-energy solutions through a partnership with ReWorld. Key outcomes included:

- **196 tonnes** of waste diverted from landfill
- **265 MWh-e** renewable energy generated
- **25 homes** powered for one year
- **482 barrels** of fuel oil saved

This initiative strengthened circularity across our operations.



Canada electric vehicle fleet transition

Across our Greater Toronto sites, we expanded the deployment of electric vehicles (EVs) to reduce emissions associated with inter-site transportation and operational activities. Transitioning to EVs supports our broader sustainability efforts by lowering Scope 1 emissions, reducing fuel consumption, and adopting low-carbon mobility solutions within our operations.



Multi site LED lighting initiative

We continued progressing with the transition to energy efficient LED lighting across multiple sites. This initiative reduces electricity consumption, lowers operational costs, and improves lighting quality and safety for employees. As more facilities complete the switch, we expect to see measurable reductions in energy use and associated greenhouse gas emissions.

Based on findings from two multi-day, on-site audits, we used insights to guide prioritization of future initiatives aimed at optimizing processes and influencing user behaviours to improve resource efficiency, saving operating costs and reducing emissions. We are further evaluating potential pathways to decarbonization, which will enable decisions based on the level of rigour and the timeline for setting near-term emissions reduction targets.

In 2025, we used 484,723 gigajoules (GJ) of renewable energy and 962,251 GJ of non-renewable energy. Sources of energy include total purchased electricity, natural gas, renewable, low/no carbon energy, coal, fuel oil, purchased steam, and self-generated.


8 Natural gas consumption increased in 2025 due to several region-specific factors:

- A new site was included in the calculation for the first time in 2025, resulting in an increase of 118,330.2 m³.
- A 275% increase at our Mexico site occurred due to a change in the natural gas supplier, which resulted in more accurate natural gas consumption data and a correction factor.


9 The total water use increase is due to more accurate reporting from a corrected water meter at the Richmond Hill site.

10 Sites in water stressed regions include locations in India and Mexico.


Total electricity consumed (kWh)




Natural gas use (m³)



2025 global waste generation



Water use



Green chemistry

We employ green chemistry principles to increase resource efficiency.

These efforts are guided by the Sheldon E-Factor principle, which calculates a ratio of waste generation to product production, with the end goal of designing manufacturing processes that minimize waste generation.

A core element of minimizing waste generation is eliminating or significantly reducing the use of chlorinated solvents within our commercial portfolio where possible. When a solvent is required, we prioritize using water whenever possible in the manufacturing process, as it minimizes environmental impact, making it an ideal alternative to chlorinated solvents. Research and development facilities that do use chlorinated solvents use recovery systems to try to capture distilled solvents for reuse, keeping them out of municipal wastewater systems. Additionally, we use enzyme-based catalysis and biotransformation in small molecule synthesis to yield increased efficiencies and reduce associated waste byproducts.



Waste

We continue to review and optimize disposal practices, with a focus on improving local waste reduction programs.

While much of our primary packaging requires the use of virgin materials to meet sterilization requirements and ensure product safety and efficacy, our secondary packaging, which bundles packs of products, and our tertiary packaging, which ships those bundles, offer more opportunities to reduce the amount of packaging and incorporate a greater proportion of recycled, recyclable, and/or sustainable materials. All paper-based packaging used in the Canadian facilities is certified by the Forest Stewardship Council (FSC) and we plan to leverage our Global Supplier Code of Conduct to explore increased collaborations that prioritize innovative and sustainable packaging solutions, as well as waste reduction scenarios.

Responsible waste practices don't just end at our property line but extend into the patients' homes. That is why Apotex supports several stewardship programs across North America aimed at ensuring the consumer is properly handling their waste. In Canada, Extended Producer Responsibility (EPR) programs are maturing, with many provinces imposing regulations for consumer medications and sharps. To that end, Apotex has been an early partner with the Health Product Stewardship Association (HPSA) to support the preservation of our environment and the protection of communities by managing take-back programs for unused or expired medications. Apotex is supporting similar medication returns programs in several jurisdictions throughout the U.S. and in Mexico City. In addition, Apotex supports Printed Paper and Packaging stewardship programs across Canada that support municipalities to properly collect and recycle these materials and provide the necessary communication and education to consumers.

Water

We recognize water as a shared resource and commit to responsible stewardship and promoting water circularity.

We use water for production sanitation and as an ingredient in some products. Some sites have implemented closed-loop cooling systems, and most sites recycle water for repurposing in various applications, including utilities, toilets and gardening. The implementation of a purified water reverse osmosis system to abate water waste and optimize system operation will save six million gallons of water per year used by two of Apotex's largest sites.

We collaborate with and empower local site leadership to develop programs that manage resource consumption and minimize waste.

Air emissions

We seek to comply with regulations to reduce fugitive emissions and have enacted a strategy to manage associated odor and noise to minimize impact on employees and surrounding communities.

Our solvent abatement systems and recovery systems help prevent the release of emissions into the atmosphere. We continue to monitor and assess our operations to identify additional opportunities for reducing emissions and/or mitigating their effects.

Social impact

Health & safety

EHS principles shape our everyday decisions.

Each global manufacturing facility has a dedicated team overseeing environment, health, and safety (EHS) responsibilities. This team reports into site leaders and works collaboratively with our global EHS function, all of which sits under the purview of our Chief Operations Officer.

We have begun integrating incident tracking software across our enterprise. This platform helps consolidate data related to EHS events, including near misses and unsafe conditions, to more readily enable our leaders to track incidents and ensure resolution. We also advanced our internal governance through the launch of our first-ever global EHS internal audit framework and initiated Process Safety Management (PSM), completing the first round of PSM assessments across our manufacturing sites.

Regular EHS assessments help us proactively identify hazards and provide actionable insights that drive improvements and reinforce accountability.



When incidents do occur, leaders investigate underlying causes and implement corrective actions to prevent recurrence. In 2025, we strengthened our approach by delivering workshops that equipped leaders with the skills to conduct meaningful investigations and by expanding our EHS index to better represent EHS performance.

Established governance structures manage risks related to the health and safety of our employees. Our Medical Advisory Committee evaluates worker health risks associated with handling pharmaceutical materials. In-house toxicologists assess all new pharmaceutical molecules to mitigate potential employee and patient exposure. We seek to minimize the use of toxic substances in our manufacturing processes and design chemical procedures to eliminate the need for harsh chemicals that would otherwise pose a potential risk to our employees. These safety structures minimize exposure risks to our valued colleagues.



HIGHLIGHT STORY:

Building on our focus to eliminate workplace injuries, a safety observation workshop was developed and delivered in 2025. The full-day workshop invited EHS participants from all our operations to learn more about leading safety indicators and their value, how to engage in safety discussions with our employees, and ultimately how to design and deliver a ‘safe day.’ Replacing the simple ‘loss’ metrics, which count only injuries and illnesses sustained reactively, the ‘safe day’ construct will be rolled out by all sites in 2026, as EHS leaders cascade a condensed version of the workshop to their sites.



11 The lost time injury rate (LTIR) measures the number of work related injuries that result in time away from work per 100 employees.
12 The lost time injury severity rate (LTISR) measures the total number of lost workdays due to injuries per 100 employees.
13 The total recordable injury rate (TRIR) measures all OSHA recordable injuries per 100 employees.



Talent attraction, retention, & development

We are “A Force for Health” and strive to empower all employees to advance our shared journey of health.

We are committed to building a high-performing, highly engaged culture where teamwork thrives and sustainable employment and rewarding career opportunities are fostered for employees, driving greater patient care and improved access to medicines.

In 2025, we remained committed to retaining our talented employees and fostering long-term careers, with 16% of our workforce having dedicated 20+ years at Apotex, and 48% of our employees with a tenure of 10+ years.

Talent attraction

We are committed to retaining talented colleagues and providing them with long-term job stability. Aligned with our Winning Behaviours, particularly Continuous Improvement, we actively seek employee perspectives through surveys and engagement initiatives, using their feedback to drive positive change and strengthen the employee experience.

Learning and skills development are central to fostering a culture of Continuous Improvement, enabling employees to build new capabilities and perform at their best.

We offer personalized development opportunities and access to global learning platforms and programs, and engage high-performing talent in mentorship programs and training initiatives, to enhance the skills and potential of every colleague. Through our Early Talent Program, we invest in building our talent pipeline by partnering with top-tier universities to help emerging talent in STEM programs gain the experience, skills, and opportunities needed to become tomorrow’s industry leaders.

We participate in community and academic career fairs and offer internship opportunities to students from Northeastern University (Toronto), the Schulich School of Business (Toronto), Rotman School of Business (Toronto), and Nova Southeastern University (Florida). As a long-standing donor to Nova Southeastern University’s Barry and Judy Silverman College of Pharmacy, we fund up to two student internships per term, helping to develop future healthcare and pharmaceutical professionals through meaningful hands-on learning experiences.

Supplier engagement

We recognize the importance of comprehensively assessing our value chain and sourcing processes.

Our Global Supplier Code of Conduct establishes clear criteria for good business practices, including human rights, ethics, health and safety, vendor management, and environmental standards. All suppliers are required to comply with our Global Supplier Code of Conduct. These requirements are embedded throughout the supplier lifecycle, including onboarding, contracting, and ongoing performance management.

Detailed in our [2025 Fighting Forced Labour & Child Labour in Supply Chains Act Report](#), we leverage third-party tools and platforms to conduct risk screening, monitoring, and data collection, enabling the identification and prioritization of high-risk suppliers. Where potential risks or non-conformances are identified, we engage suppliers to implement corrective actions and strengthen controls, supporting continuous improvement over time.



Corporate citizenship



Apotex Global Health Access Fund

Building on Apotex's legacy of giving, this fund focuses on addressing unequal access to care and low health literacy in communities facing poor social determinants of health, where race, economic status, and other factors create barriers to access. In two years, the fund provided \$1.5 million in funding to grant recipients in Canada, the U.S., India, and Mexico.

Partnership with Health Partners International of Canada

Our partnership with Health Partners International of Canada (HPIC) continues for more than two decades. Through this long-standing collaboration, we have delivered over \$46 million in essential medicines to communities in nearly 80 countries, reaching more than 33 million people and providing life-saving medications and healthcare resources to those who need them most.

Community support

In 2025, Apotex donated approximately \$1 million (market value) in essential Apotex products to vulnerable populations through our medicine donation programs.

Within the Greater Toronto Area, we regularly donate to the Shelter Health Network, which serves high-risk populations without stable housing and with complex health needs. We also support Yonge Street Mission, a social service provider that works directly with vulnerable individuals and families in Toronto to help end the cycle of poverty and to support its Evergreen Health Centre.



HIGHLIGHT STORY

Oak Valley Health's Markham Stouffville Hospital (MSH)

In November 2025, Apotex supported Oak Valley Health in responding to urgent capacity needs driven by rapid community growth.

To help address these pressures, we donated a 16,000-square-foot modular building, now named the Apotex Administrative Building, along with a \$100,000 contribution to fund the hospital's highest priority equipment needs. The modular facility, repurposed from Apotex's own operations, was relocated to the hospital site and is used to house several key administrative teams. This move frees up critical space within the hospital, creating room to expand the Emergency Department and support the region's growing demand for care.

Appendix

Links to company policies

- [!\[\]\(133590ab0b9ecaa87787f1547adb1252_img.jpg\) Code of Conduct](#)
- [!\[\]\(c48b4a99ad40441fe8fbd4e0e5325a3f_img.jpg\) Global Supplier Code of Conduct](#)
- [!\[\]\(c7fd93e5fef82f60754eea0e0aaaf6e0_img.jpg\) Global Environment, Health and Safety \(EHS\) Policy](#)
- [!\[\]\(339374c82bf1dad29917e85ecb16399b_img.jpg\) Global Competition Law Policy](#)
- [!\[\]\(a7204fa446bca4a87911f54be2e85e2e_img.jpg\) Global Conflicts of Interest](#)
- [!\[\]\(cd6f1891a25f3696e4050134b165a777_img.jpg\) Global Lobbying and Political Contributions Policy](#)
- [!\[\]\(b4ee2e5790823ec3354c4c1adf07bcfd_img.jpg\) Global Speaking Up Policy](#)
- [!\[\]\(24f6860c14355be77b5a914a2e8244ab_img.jpg\) Fighting Forced Labour & Child Labour in Supply Chains Act \(EN\)](#)

